# OnCo record nct02815033 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02815033/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02815033", "NCT02815033" ;
  schema:name "Imaging Staging and Response Prediction in Metastatic Hormono-Sensitive Prostate Cancer Patients Receiving Enzalutamide"@en ;
  schema:description "A phase 2 trial of Whole-body MRI in Prostate cancer, run by The European Uro-Oncology Group, completed."@en ;
  schema:url <https://onco.cc/trials/nct02815033/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02815033> ;
  onco:status "completed" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/whole-body-mri/> ;
  onco:drugs <https://onco.cc/drugs/enzalutamide/> .